Peroxisome proliferator-activated receptor gamma (PPARG)
Also known as: PPAR-γ, PPARG, PPARg, nr1c3
Nuclear receptor (PPARG) activated by thiazolidinediones (pioglitazone, rosiglitazone) that regulates insulin sensitivity in peripheral tissues. It is the therapeutic target of thiazolidinediones in type 2 diabetes.
Drugs that activate PPAR-γ (thiazolidinediones) improve insulin sensitivity but may cause fluid retention, heart failure and fractures; combination with insulin or sulfonylureas increases hypoglycaemia risk.
Contraindicated in heart failure (class III/IV) and active liver disease; monitor weight, oedema and cardiac symptoms. Increased fracture risk (especially women).
